Viewpoint | Published:

Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 180181 (2006) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454–1457

  2. 2.

    (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245–262

  3. 3.

    et al. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115: 94–101

  4. 4.

    et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238–4245

  5. 5.

    et al. (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646–6656

  6. 6.

    et al. (2006) PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91: 213–220

  7. 7.

    et al. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373–6379

  8. 8.

    et al. (2005) High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90: 5265–5269

  9. 9.

    et al. (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399–5404

  10. 10.

    et al. Inhibitors of raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res, in press

Download references

Author information

Affiliations

  1. L Groussin is a visiting post-doctoral fellow (from Groupe Hospitalier Cochin, Paris, France) and JA Fagin is a Professor of Medicine in the Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

    • Lionel Groussin
    •  & James A Fagin

Authors

  1. Search for Lionel Groussin in:

  2. Search for James A Fagin in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to James A Fagin.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncpendmet0161

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing